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The outcome of viral infections depends on a complex
set of interactions between the viruses and their hosts.
Particularly, viral infection triggers specific signaling pro-
grams within the infected cells that results in substantial
changes in host gene expression. While some of these
changes might be beneficial for viral replication, others rep-
resent the induction of a host antiviral response. In this
respect, viruses have evolved genes that counteract this
initial innate antiviral response. These viral-host interac-
tions shape the subsequent phases of the disease and
influence the adaptive immune response. In influenza
viruses, the nonstructural protein 1 inhibits the interferon-
mediated antiviral response. The regulatory activities of this
viral protein play a major role in the pathogenicity of influen-
za virus and appear partially responsible for the ability of
influenza viruses to infect multiple animal species, which
likely contributes to the generation of new pandemic virus-
es in humans.
C
oevolution of pathogens with their hosts has resulted
in the shaping of the host immune system. A major
component of this system is the innate immune response,
which includes all the host barriers and responses with
broad specificity against pathogens. The innate immune
response not only represents the first barrier against infec-
tion but also provides the appropriate signals required for
the subsequent adaptive cellular and humoral immune
responses to develop. The type I interferon (IFNα/β)
response constitutes a critical element of the innate
immune system that is particularly important in the battle
against viral pathogens. Secretion of IFNα/β results in the
induction of a cellular antiviral response involving the
transcriptional upregulation of >100 genes (1).
Despite the host’s sophisticated immune system, virus-
es continue to successfully infect them and cause disease
and, in some cases, death. The success of viruses is
explained, at least in part, by the acquisition of viral genes
during evolution that antagonize the host immune
response. Viral-encoded IFNα/β antagonists are of partic-
ular interest, since they appear to be present in most animal
viruses. We detail how influenza viruses evade the host
innate immunity, with particular emphasis on the IFNα/β
response, and the implications of this immune evasion in
pandemic influenza.
IFNα α/β β Antiviral Response
Animal cells that sense viral infection respond almost
immediately by synthesizing and secreting IFNα/β. The
IFNα/β genes include IFNβ and many closely related
IFNα genes. Most cells have intracellular sensors of viral
products that, when activated, initiate a signaling cascade
that results in transcriptional induction of the IFNβ gene.
The nature of these sensors has remained unknown until
recently, when 2 putative RNAhelicases, RIG-I and MDA-
5, were identified as sensors for viral dsRNA generated in
the cytoplasm during viral infection (2–4). Binding to
dsRNA by these proteins may result in initiation of heli-
case activity, concomitant with a conformational change
that leads to recruiting additional cellular factors, includ-
ing the recently identified IPS-1/MAVS protein (5,6). As a
result, different cellular kinases, including the IRF3 kinas-
es TBK1 and IKKε, become activated. Activated IRF3,
together with NF-κB and AP-1, accumulate in the nucleus,
bind to the IFNβ promoter, and stimulate transcription.
While cytoplasmic viral dsRNA is one of the viral mole-
cules that trigger this cascade, other viral products and
other cellular sensor molecules also likely participate in
the induction of IFNβ. IFNα/β induction is also stimulat-
ed by the presence of viral RNAand DNAin the endosome
through the action of TLR3, TLR7, TLR8, or TLR9 (7).
Different cell subtypes appear to employ different mecha-
nisms to recognize viral products (8).
Once IFNα/β has been synthesized, it is secreted and
binds to the IFNα/β receptor. All IFNαs and IFNβ bind to
the same receptor and as a result, the cytoplasmic kinases
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STAT1 and STAT2 molecules. This process promotes gen-
eration of the ISGF3 transcription factor, a complex of
STAT1, STAT2, and IRF9 that accumulates in the nucleus.
Nuclear ISGF3 binds to promoters that contain interferon-
stimulated response elements and stimulates the transcrip-
tional induction of antiviral genes, including MxA, PKR,
OAS, ADAR, PML, p56, and many others (9). These IFN-
stimulated genes inhibit viral replication by many different
mechanisms, including binding to viral nucleocapsids,
translation inhibition, RNAdegradation, RNAediting, and
apoptosis induction. Moreover, secreted IFNα/β promotes
the generation of robust cellular and humoral immunity
(10,11). In general, the IFNα/β response has a complex
regulation that involves positive and negative feed-back
mechanisms, some of which are still unknown.
Nonstructural Protein 1 of Influenza Virus
Although IFNα/β was first described as a factor with
antiviral activity secreted by cells treated with partially
heat-inactivated influenza A viruses (12), it was also rec-
ognized early on that influenza viruses are poor IFNα/β
inducers (13). This is because influenza viruses, like many
other viruses, encode mechanisms to evade and antagonize
the IFNα/β response (14). In the case of influenza Avirus,
this IFNα/β antagonistic function is encoded by the non-
structural protein 1 (NS1) gene.
NS1 of influenza A viruses is encoded by the unspliced
mRNA derived from the shortest RNA segment of the 8
viral RNA segments. The protein is the most abundant
nonstructural viral protein expressed in influenza A
virus–infected cells. The development of reverse genetics
techniques to manipulate the influenza virus genome made
it possible to generate NS1 mutant viruses, including a
recombinant influenza A virus lacking the NS1 gene (15).
The NS1 knockout influenza Avirus, delNS1, was replica-
tion defective in most cells and hosts, except for those
lacking a functional IFNα/β system. Most remarkable,
delNS1 virus was highly attenuated in mice but replicated
and caused disease in STAT1 knockout mice, which lack
one of the key transactivator molecules needed for the
IFNα/β response (15). These results indicate that NS1 is
required to overcome the IFNα/β response during influen-
za A virus infection.
The basis of the IFNα/β antagonistic properties of the
NS1 of influenza A virus relies on its ability to prevent
IFNβ synthesis; this explains the poor IFNβ–inducing
properties of influenza Aviruses (16,17). In the absence of
NS1, influenza A virus becomes a high IFNα/β–inducing
virus, and induction of high levels of IFNα/β results in
inhibition of replication of delNS1 virus. NS1, by virtue of
its dsRNA binding properties, is likely to sequester viral
dsRNA produced during viral infection, which prevents
recognition of this dangerous molecule by cellular sensors.
This model of action is consistent with the ability of NS1
expression to prevent activation of transcription factors
involved in the induction of IFNα/β synthesis, including
IRF3 (16). Moreover, dsRNA binding is required for opti-
mal inhibition of IFNβ production by NS1 (18). Similar
results were obtained with the NS1 of influenza B virus
(19,20). However, interactions of NS1 with cellular pro-
teins also likely contribute to its IFNα/β antagonistic func-
tions (21). NS1 of influenza Avirus, but not of influenza B
virus, inhibits cellular factors involved in mRNA process-
ing (22,23); this function might also play a role in inhibit-
ing IFNα/β production by influenza A virus (24). Finally,
NS1 has also been shown to have IFNα/β inhibitory prop-
erties at a post-IFNα/β synthesis level. The NS1 of both
influenza A and B viruses prevents the activation of the
translation inhibitory and IFN inducible protein PKR
(25,26); the NS1 of influenza B virus inhibits the activity
of ISG15 (27), an IFN-inducible protein that enhances the
IFN-mediated antiviral response.
Role of NS1 Gene 
Influenza A viruses can infect many different animal
species, such as different birds (e.g., waterfowl, chickens,
turkeys), horses, pigs and humans, but also cross species,
with avian strains infecting mammalian species, including
humans. This property is especially critical during human
pandemics that are characterized by novel antigenic deter-
minants. These determinants derive from avian strains for
which no immunity exists in most human population,
which results in higher illness and death rates. The factors
involved in the ability of an avian influenza virus strain, or
of a reassortant virus containing avian antigenic determi-
nants, to infect and propagate in humans are poorly under-
stood; this lack of knowledge hampers our ability to
predict the pandemic potential of avian influenza virus
strains circulating in birds. Although the receptor specifici-
ty of the hemagglutinin protein is a factor that appears to
be important for human adaptation of avian strains, other
poorly understood factors also participate in this adapta-
tion (28). With respect to NS1, viral strains from different
animal hosts likely have NS1 genes adapted to antagonize
the IFNα/β system of their specific host species. This was
the case when the NS1 gene of the human influenza A
virus that caused the 1918 H1N1 pandemic was compared
with the NS1 gene of the mouse-adapted H1N1 influenza
A virus strain WSN. Replacement of the NS1 gene of
WSN virus with that of the 1918 virus resulted in an atten-
uated virus in mice, but this virus more efficiently inhibit-
ed the IFNα/β system in human cells (21,29). This
inhibition might be explained by specific interactions of
NS1 with host factors that have different sequences
depending on the host, with NS1 of a mouse-adapted strain
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tors, and vice versa. If this is a general property of NS1
from different influenza virus strains, an avian strain
would require adaptation of its NS1 gene to efficiently
antagonize the human IFNα/β system. Alternatively, an
avian strain would require acquisition by reassortment of
an NS1 gene from a human strain to efficiently infect and
propagate in humans.
Because mutations that affect NS1 function also have a
profound effect on viral pathogenicity, highly pathogenic
influenza virus strains may have an NS1 gene with partic-
ularly strong IFNα/β antagonistic properties. Moreover,
the ability of NS1 to attenuate the activation of different
transcription factors during viral infections has implica-
tions beyond the inhibition of IFNα/β synthesis. For
instance, expression of many other cytokines and mole-
cules involved in activation of dendritic cell function also
appear to be regulated by NS1 (30). In this respect, the
NS1 of the highly pathogenic avian H5N1 viruses circulat-
ing in poultry and waterfowl in Southeast Asia might be
responsible for an enhanced proinflammatory cytokine
response (especially TNFα) induced by these viruses in
human macrophages (31,32). High levels of proinflamma-
tory cytokines are likely to play an important role in the
unusual lethality of these viruses in humans. Fortunately,
infection with these viruses appears to be rare and the
viruses have not been able to efficiently propagate from
human to human.
Other Influenza Antagonists of Host Response
Although delNS1 influenza virus is a high inducer of
IFNα/β, partial UV inactivation of this virus results in
even higher induction of IFNα/β (33). These results sug-
gest the presence of additional viral genes besides NS1 that
attenuate IFNα/β production during viral infection and
that become inactivated by UV. The viral polymerase, pos-
sibly through its endonuclease “cap-snatching” activity,
might be responsible for this anti- IFNα/β activity (33).
Further experimentation will be required to evaluate this
hypothesis. In any case, the presence of multiple viral
genes that cooperatively antagonize the IFNα/β response
is not uncommon among the different virus families.
Influenza A virus encodes a second nonstructural
polypeptide in virus-infected cells, the PB1-F2 protein
(34). This protein is encoded by an alternative open read-
ing frame of the PB1 RNAsegment, which also directs the
synthesis of the PB1 protein, a critical component of the
viral polymerase. The PB1-F2 protein localizes to the
mitochondria of the infected cells (35) where it interacts
with 2 components of the mitochondrial permeability tran-
sition pore complex, ANT3 and VDCA1, that are thought
to play a major role in apoptosis control (36). As a result,
expression of PB1-F2 sensitizes cells to apoptosis. This
process might constitute an important immune evasion
strategy. Thus, a PB1-F2-knockout influenza A virus
induced less cell death than the wild-type virus in infected
human monocytes, which suggests that expression of PB1-
F2 affects immune cell function during viral infection (34).
Although several influenza A virus strains that lack PB1-
F2 occur naturally, PB1-F2 likely contributes to viral path-
ogenicity and might have an important role in determining
the severity of pandemic influenza.
NS1 as Target for Antivirals and Vaccines 
Our knowledge of NS1 function might be applied in the
near future to select for new antiviral compounds against
influenza virus. Predictably, small molecules that interfere
with the ability of NS1 to bind dsRNA or prevent IFNα/β
production will also enhance the host innate immunity
against influenza virus, resulting in faster viral clearance.
In addition, recombinant influenza viruses with impaired
NS1 function might represent efficient live attenuated vac-
cines against influenza. These viruses can be grown in
IFNα/β-deficient substrates to high titers, but they are
attenuated in the host (37). Moreover, since the inhibitory
effects of NS1 attenuate aspects of both innate and adap-
tive immunity, NS1 mutant viruses appear to be intrinsical-
ly more immunogenic (38). Recombinant influenza viruses
with modified NS1 genes have been developed and have
proven to be attenuated and immunogenic in different ani-
mal models. These modified viruses might be used in the
future as the basis of live vaccines against epidemic and
pandemic influenza (37–40).
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